List of Excipients in Branded Drug DIBENZYLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	DIBENZYLINE	phenoxybenzamine hydrochloride	59212-001	D&C RED NO. 33
Advanz Pharma (US) Corp	DIBENZYLINE	phenoxybenzamine hydrochloride	59212-001	FD&C RED NO. 3
Advanz Pharma (US) Corp	DIBENZYLINE	phenoxybenzamine hydrochloride	59212-001	FD&C YELLOW NO. 6
Advanz Pharma (US) Corp	DIBENZYLINE	phenoxybenzamine hydrochloride	59212-001	GELATIN

Dibenzyline Excipient Strategy and Commercial Opportunities for Phenoxybenzamine

Last updated: August 4, 2026

Dibenzyline is the U.S. brand for phenoxybenzamine hydrochloride, an irreversible, nonselective alpha-adrenergic blocker used primarily in pheochromocytoma and paraganglioma management. Its core molecule is long off-patent, and commercial differentiation depends more on supply reliability, excipient selection, dosage-form performance, and regulatory execution than on composition-of-matter exclusivity.

The strongest opportunities are generic or 505(b)(2) products that improve capsule availability, address lactose or gelatin restrictions, reduce excipient-related intolerance, strengthen stability, or create an alternative dosage form. The market is specialized and relatively small, but phenoxybenzamine has clinical value in a narrow high-acuity population where shortages and sourcing interruptions can create commercial leverage.

What is Dibenzyline and how is phenoxybenzamine used?

Dibenzyline contains phenoxybenzamine hydrochloride in an oral capsule. The product is indicated for the preoperative management of patients with pheochromocytoma and for controlling episodes of hypertension and sweating associated with catecholamine excess. It is also used in selected patients with neurogenic bladder and other conditions involving excessive sympathetic tone, subject to physician judgment and applicable labeling [1].

Phenoxybenzamine produces prolonged alpha-adrenergic blockade through covalent interaction with alpha receptors. Its pharmacology differentiates it from reversible alpha blockers such as doxazosin and prazosin.

Dibenzyline product profile

Attribute	Product information
Brand	Dibenzyline
Active ingredient	Phenoxybenzamine hydrochloride
Dosage form	Oral capsule
U.S. strength	10 mg
Drug class	Irreversible, nonselective alpha-adrenergic blocker
Primary use	Pheochromocytoma and paraganglioma management
Sponsor or manufacturer	Validus Pharmaceuticals is identified in U.S. product materials
FDA pathway	Approved under an original NDA; generic competition may use ANDA pathways
Commercial category	Low-volume, specialty cardiovascular and endocrine product

Dibenzyline is not a biologic. Biosimilar competition is therefore irrelevant. The competitive threats are authorized generics, conventional ANDA products, compounded products in limited circumstances, and alternative alpha-blocker therapies.

What excipients are used in Dibenzyline capsules?

Public product labeling identifies the inactive ingredients in the commercial capsule formulation. The exact qualitative and quantitative excipient composition should be confirmed against the current FDA-approved prescribing information, DailyMed record, and the sponsor’s current container labeling before making a regulatory or formulation decision [1,2].

Historically and currently marketed capsule products in this category may use combinations of:

• Lactose or another diluent
• Microcrystalline cellulose
• Corn starch or another disintegrant
• Magnesium stearate
• Colloidal silicon dioxide
• Gelatin capsule shell
• Titanium dioxide and approved capsule colorants

The commercial opportunity is not created by simply replacing an excipient. A formulation change must preserve dissolution, content uniformity, stability, capsule integrity, impurity control, and bioequivalence.

Excipient risk points

Excipient issue	Potential commercial impact	Development response
Lactose intolerance or milk-derived excipient concern	Restricts use in sensitive patient groups and institutions with excipient-screening policies	Develop a lactose-free composition and document source controls
Gelatin capsule shell	Limits suitability for vegetarian, religious, or selected institutional requirements	Evaluate hypromellose or pullulan capsules
Colorants	Can create patient preference, labeling, or market-access concerns	Use a colorant-free or reduced-color capsule
Magnesium stearate variability	May affect lubrication, disintegration, and dissolution at low drug loading	Control grade, surface area, mixing time, and concentration
Moisture sensitivity	Can affect capsule shell quality and drug stability	Use appropriate packaging, desiccant strategy, and accelerated stability studies
Low-dose uniformity	Phenoxybenzamine is administered at relatively low doses, increasing blend-uniformity sensitivity	Use engineered blending, granulation, or ordered mixing
Excipient supply disruption	Can interrupt production of a low-volume product with limited qualified suppliers	Establish dual sourcing and functional-equivalence specifications

What excipient strategy is most attractive for Dibenzyline?

The best initial strategy is a robust immediate-release capsule with a simplified excipient system and a clear patient-access claim. A developer should avoid unnecessary formulation complexity because the product is a low-volume oral solid with a mature reference formulation.

Lactose-free formulation

A lactose-free capsule could target patients with lactose intolerance and hospitals that prefer standardized excipient policies. Suitable diluent systems may include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or combinations selected for compatibility and dissolution.

Mannitol can improve mouthfeel and powder handling but may introduce hygroscopicity or tabletability considerations. Microcrystalline cellulose is widely understood by regulators and contract manufacturers, but its bulk density and flow characteristics can complicate low-dose blend uniformity.

Non-gelatin capsule

A hypromellose capsule could expand access for patients avoiding animal-derived gelatin. The commercial value is likely greater in institutional and specialty-pharmacy channels than in the general retail market.

A non-gelatin shell requires evaluation of:

• Moisture transfer
• Shell brittleness
• Fill-weight consistency
• Disintegration
• Packaging compatibility
• Stability under temperature and humidity stress

A capsule-shell change may be technically manageable, but it still requires comparative dissolution and bioequivalence support.

Colorant-free formulation

A white or uncolored capsule can reduce excipient complexity and may improve acceptance among patients concerned about dyes. The opportunity is modest unless paired with lactose-free or non-gelatin positioning.

Modified-release or liquid formulation

A liquid or modified-release phenoxybenzamine product could address swallowing difficulty or individualized titration. It would also create substantially higher regulatory and clinical risk.

Phenoxybenzamine dosing is titrated according to blood-pressure response and adverse effects. A liquid formulation could support smaller dose increments, but the developer would need to establish chemical stability, preservative effectiveness if applicable, dose uniformity, container compatibility, and in-use stability.

A modified-release dosage form would require a stronger clinical rationale because the pharmacologic effect is already prolonged. It could alter tolerability, onset, perioperative control, and titration behavior. This is a higher-risk 505(b)(2) opportunity than a conventional capsule.

What patents protect Dibenzyline and phenoxybenzamine?

The original composition-of-matter and early formulation patents for phenoxybenzamine are expired. Dibenzyline does not have a contemporary patent estate comparable to newer specialty drugs.

Patent and exclusivity profile

Category	Dibenzyline status
Composition-of-matter patent	Expired
Original formulation patent	Expired or commercially immaterial
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	No current exclusivity identified for the legacy product
Pediatric exclusivity	No current exclusivity identified
Method-of-use patents	Potentially possible for new indications, but no core current barrier is apparent
Formulation patents	Possible only for a newly developed dosage form or excipient system
Biosimilar protection	Not applicable
Generic entry barrier	Primarily technical, regulatory, and commercial

A new patent could potentially cover a specific excipient composition, capsule shell, stabilization system, liquid formulation, particle-size distribution, or dosing method. Such protection would need to satisfy novelty, non-obviousness, written-description, and enablement requirements. A patent covering only routine substitution of lactose with another conventional diluent would face material validity risk.

What is the Orange Book status of Dibenzyline?

Dibenzyline is listed in FDA drug-product databases as a prescription phenoxybenzamine hydrochloride capsule. The Orange Book is the relevant source for reference-product designation, therapeutic-equivalence codes, patent listings, and exclusivity information [3].

For an ANDA applicant, the central issues are:

1. Identifying the correct reference listed drug.
2. Matching strength, dosage form, route, and labeling requirements.
3. Reviewing current patent and exclusivity listings.
4. Assessing whether a Paragraph IV certification is necessary.
5. Demonstrating bioequivalence and pharmaceutical equivalence.

Because the key patent terms are historical and the product is mature, a new entrant is more likely to face ordinary ANDA requirements than a meaningful patent-blocking period. The Orange Book should be checked at filing and again before launch because listing status can change.

When does Dibenzyline lose exclusivity?

Dibenzyline’s principal statutory exclusivity periods have long expired. The product’s commercial protection now depends on manufacturing capability, regulatory approval, supply reliability, distribution, and clinical familiarity.

Exclusivity timeline

Event	Approximate status
Original phenoxybenzamine approval	Legacy approval; original exclusivity expired
Early molecule and formulation patents	Expired
Current brand protection	Trademark and commercial branding rather than meaningful patent exclusivity
Generic pathway	ANDA competition is legally available, subject to FDA approval
New formulation protection	Could arise only from a separately patentable product or method

A commercial entrant should not assume that the absence of a major blocking patent eliminates launch risk. Low-volume products can encounter supplier qualification delays, bioequivalence failures, manufacturing deviations, and limited active-pharmaceutical-ingredient availability.

Which companies are challenging Dibenzyline?

The competitive field includes the brand sponsor, generic manufacturers, and potentially specialty manufacturers that source phenoxybenzamine through contract development and manufacturing organizations.

Publicly available FDA product databases and commercial drug listings should be used to identify currently approved generic applicants and active National Drug Codes. Generic availability can vary by strength, manufacturer, and supply period.

The likely competitive groups are:

• The Dibenzyline brand product
• Approved phenoxybenzamine hydrochloride capsule manufacturers
• Authorized-generic or brand-equivalent suppliers
• Specialty distributors serving endocrine surgery centers
• Compounding pharmacies, where legally permissible and clinically appropriate

A company does not need a patent challenge to compete. For a legacy product, the relevant entry route is usually an ANDA with Paragraph III or Paragraph I certification if no unexpired relevant patent blocks approval. A Paragraph IV filing would be relevant only if an unexpired listed patent covered the reference product.

What Paragraph IV risks exist for phenoxybenzamine?

Paragraph IV risk is likely limited because the principal patent terms associated with phenoxybenzamine and the original Dibenzyline product are historical. The more important risks are regulatory and technical.

ANDA risk areas

• Failure to match the reference product’s dosage form and release characteristics
• Inadequate low-dose blend uniformity
• Dissolution differences caused by lubricant level or capsule shell
• Incomplete impurity or degradation-product characterization
• Failure to establish stability through the proposed shelf life
• Labeling differences that FDA will not accept
• Difficulty sourcing qualified phenoxybenzamine hydrochloride API
• Manufacturing economics that do not support a low annual volume

A Paragraph IV strategy would have limited value unless a current listed patent is identified. A formulation-patent strategy could be more relevant for a differentiated product, but any patent must protect a non-routine technical solution rather than an ordinary excipient substitution.

What formulation patents could protect a new phenoxybenzamine product?

A new entrant could pursue patents in several areas.

Excipient composition patents

A claim could cover a defined combination of diluent, disintegrant, lubricant, glidant, and capsule shell. Patent strength would improve if the formulation demonstrates an unexpected result, such as:

• Improved content uniformity at low drug load
• Faster or more consistent dissolution
• Lower degradation under high humidity
• Improved capsule-shell stability
• Reduced food effect
• Better chemical compatibility with the API

Liquid formulation patents

A liquid product could be protected through:

• A specific solvent or cosolvent system
• pH-controlled stabilization
• Preservative system
• Low-sorption container closure
• Defined concentration range
• In-use stability after opening

The product must also show a clinically relevant benefit. A liquid that only changes presentation without improving dosing or administration may have limited commercial value.

Method-of-use patents

Potential method claims could address:

• Titration protocols for pheochromocytoma
• Perioperative alpha blockade
• Treatment of selected neurogenic bladder populations
• Use in patients unable to tolerate reversible alpha blockers
• Combination treatment with beta blockers under a specified sequence

Method-of-use patents would face prior-art and obviousness scrutiny. The most credible claims would require a defined patient population, dosing regimen, or clinically demonstrated outcome.

How strong is the Dibenzyline patent estate?

The legacy Dibenzyline patent estate is weak as a barrier to generic entry. The product’s defensibility is operational rather than patent-based.

Patent-strength assessment

Factor	Assessment
Blocking composition patent	None expected to remain in force
Blocking formulation patent	Limited or absent for the legacy capsule
Method-of-use protection	No broad current barrier identified
Manufacturing know-how	Potentially meaningful, particularly for low-dose uniformity and API handling
Regulatory complexity	Moderate
Supply-chain barrier	Potentially meaningful because of specialized, low-volume demand
Brand loyalty	Moderate in specialist settings
Generic substitution risk	High once reliable approved supply is available

A new patent portfolio would be strongest if it combines composition claims, process claims, and clinical-use claims around a genuinely differentiated product. A single narrow excipient claim would provide limited protection.

What commercial opportunities exist for Dibenzyline excipients?

The opportunity is a specialty-generic platform rather than a mass-market excipient program.

Priority commercial opportunities

1. Lactose-free capsule

This is the most practical differentiation route. It requires modest development investment and can support institutional procurement, specialty-pharmacy placement, and patient-access messaging.

2. Non-gelatin capsule

A hypromellose capsule can address dietary and religious restrictions. The incremental market may be limited, but it can provide a clear product distinction where the reference product uses gelatin.

3. Dual-source excipient platform

A manufacturer can reduce supply risk by qualifying more than one supplier for each critical excipient. This strategy has value in a low-volume product because a single excipient disruption can stop production.

4. Improved low-dose blend

A formulation engineered for content uniformity can reduce batch failure risk and improve regulatory confidence. This is primarily a manufacturing advantage, but it may support process patents or trade-secret protection.

5. Liquid or titratable dosage form

A liquid formulation could support pediatric, geriatric, dysphagic, or highly individualized dosing markets. It has greater development risk and may require a 505(b)(2) application rather than a conventional ANDA, depending on the product’s relationship to the reference drug.

6. Hospital shortage and continuity supply

Phenoxybenzamine is used in specialized endocrine and surgical settings. A manufacturer with dependable supply, short lead times, and strong hospital contracting capabilities could compete even without a differentiated patent.

How does Dibenzyline compare with alternative alpha blockers?

Product	Mechanism	Typical commercial position	Excipient opportunity
Dibenzyline, phenoxybenzamine	Irreversible nonselective alpha blockade	Specialty use, especially pheochromocytoma	Lactose-free, non-gelatin, liquid, supply reliability
Doxazosin	Reversible alpha-1 blockade	Broad generic cardiovascular and urologic use	Limited differentiation because competition is extensive
Prazosin	Reversible alpha-1 blockade	Generic hypertension and other uses	High competition and lower product-specific leverage
Terazosin	Reversible alpha-1 blockade	Generic hypertension and benign prostatic hyperplasia	Mature, price-competitive market
Phentolamine	Short-acting competitive alpha blockade	Acute or procedural settings	Different clinical use and dosage-form requirements

Phenoxybenzamine occupies a narrower clinical position than doxazosin or prazosin. Its commercial value depends on specialist demand and product availability rather than prescription volume across primary care.

What generic launch scenarios exist for phenoxybenzamine?

Scenario 1: Conventional ANDA capsule

This is the lowest-risk path. The product would match the reference dosage form and strength, use standard excipients, and compete primarily on price and supply.

Scenario 2: Differentiated capsule

A lactose-free, dye-free, or non-gelatin capsule could support a modest premium or preferred institutional status. The regulatory pathway remains more straightforward than a liquid or modified-release product, but comparative performance must be demonstrated.

Scenario 3: 505(b)(2) liquid

A liquid could create a new dosing and administration proposition. It would require a stronger clinical and CMC package, with a longer development timeline and potentially higher approval risk.

Scenario 4: Authorized generic or supply agreement

A brand owner or specialty manufacturer could use an authorized-generic arrangement to retain channel access while competing against independent ANDA entrants. This strategy would depend on manufacturing cost, supply rights, and distribution economics.

What litigation and settlement issues affect Dibenzyline?

No major contemporary patent litigation or settlement structure is central to the legacy Dibenzyline market based on the mature status of phenoxybenzamine. The relevant legal review should focus on:

• Current Orange Book patent listings
• Active ANDA approvals
• Any Paragraph IV notices
• Product-specific litigation in federal district court
• Trademark and trade-dress restrictions
• FDA enforcement involving compounding or manufacturing

A developer should also assess whether a branded product’s capsule appearance, trade dress, or naming could create Lanham Act exposure. Those issues are separate from patent protection and do not prevent an appropriately differentiated generic from entering the market.

What FDA regulatory status applies to a new Dibenzyline competitor?

A conventional phenoxybenzamine capsule that is pharmaceutically equivalent to the reference product would generally be developed through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A materially different dosage form, formulation, or indication may require a 505(b)(2) application [4].

Regulatory pathway comparison

Product concept	Likely pathway	Key evidence
10 mg immediate-release capsule matching reference	ANDA	Pharmaceutical equivalence, bioequivalence, CMC, labeling
Lactose-free capsule	Usually ANDA if equivalence is maintained	Comparative dissolution, bioequivalence, excipient justification
Hypromellose capsule	Potentially ANDA	Shell equivalence, dissolution, stability, bioequivalence
Oral solution or suspension	Potentially 505(b)(2)	Dose uniformity, stability, clinical bridging, safety
Modified-release product	505(b)(2) or separate NDA strategy	Release characterization, clinical pharmacology, efficacy and safety

FDA’s inactive-ingredient databases and approved labeling should be used to assess precedent for proposed excipients, maximum daily exposure, route-specific use, and patient tolerability [5].

What geographic coverage and manufacturing barriers matter?

The U.S. opportunity is the clearest because FDA approval, Orange Book listing, and generic substitution can support pharmacy and hospital access. European and other markets may use different reference products, naming conventions, regulatory routes, and reimbursement systems.

Geographic considerations

• U.S.: ANDA route, Orange Book reference-product framework, specialist hospital demand
• European Union: national or decentralized procedures may apply; generic or hybrid applications depend on the reference product and formulation
• United Kingdom: separate post-Brexit regulatory procedures and supply requirements
• Canada and Australia: national generic approval and local reference-product requirements
• Emerging markets: potential demand, but pricing pressure and API registration requirements can be substantial

Manufacturing barriers

• Limited API suppliers
• Low production volume
• Need for validated low-dose blending
• Capsule-shell supplier qualification
• Stability and moisture control
• Specialized pharmacovigilance and medical-information support
• Inventory requirements for irregular but clinically urgent demand

The strongest manufacturer is likely to be one with existing specialty-generic infrastructure, validated oral-solid manufacturing, and hospital distribution rather than a large consumer-health company.

What is the revenue exposure and market size for Dibenzyline?

Public sources do not provide a reliable standalone revenue figure for Dibenzyline in the materials cited here. The product is a niche specialty medicine, and sales are likely driven by a small population of patients with pheochromocytoma, paraganglioma, and selected off-label indications.

Revenue exposure should be modeled through:

• Annual treated-patient volume
• Average maintenance duration
• Preoperative treatment cycles
• Net price per capsule
• Generic substitution rate
• Hospital and specialty-pharmacy mix
• Stocking requirements caused by supply uncertainty
• API and contract-manufacturing cost

A conventional generic may have limited absolute revenue but attractive strategic value if it is one of few reliable suppliers. A differentiated excipient product is more likely to capture share through availability and formulary preference than through broad consumer demand.

Key Takeaways

• Dibenzyline is phenoxybenzamine hydrochloride, an old, specialized alpha-blocker with no meaningful current composition-of-matter exclusivity.
• Generic entry risk is high because the core product is mature and patent barriers are limited.
• The best excipient opportunity is a lactose-free immediate-release capsule with strong content-uniformity and stability performance.
• A non-gelatin or dye-free capsule can create incremental institutional and patient-access differentiation.
• A liquid formulation is a higher-risk 505(b)(2) opportunity that may support individualized dosing.
• Patent value would depend on demonstrated technical advantages, not routine excipient substitution.
• Supply reliability, API sourcing, and specialist distribution are likely more important than patent litigation.
• Biosimilar risk does not apply because phenoxybenzamine is a small-molecule drug.
• Commercial returns are likely limited in absolute terms but may be attractive for specialty-generic manufacturers with low-volume production capability.

FAQs

Is Dibenzyline lactose-free?

The answer depends on the current commercial formulation and market-specific labeling. U.S. product labeling should be checked before concluding that a particular Dibenzyline lot or presentation is lactose-free.

Can a generic manufacturer change the capsule shell used for phenoxybenzamine?

A shell change may be possible if the product remains pharmaceutically equivalent and meets FDA requirements for dissolution, stability, bioequivalence, and labeling. A hypromellose shell could support a non-gelatin product strategy.

Is phenoxybenzamine eligible for an authorized generic?

An authorized generic could be marketed through a brand-owner or licensing arrangement, subject to applicable FDA approval and distribution requirements. The opportunity would depend on manufacturing economics and channel strategy.

Could a phenoxybenzamine liquid receive new patent protection?

Yes, but protection would require a novel and non-obvious formulation or use. A liquid composition with improved stability, dosing accuracy, or in-use performance would provide a stronger basis than a routine solvent substitution.

Does Dibenzyline have biosimilar competition?

No. Phenoxybenzamine is a small-molecule active ingredient. Competition occurs through generic, authorized-generic, specialty-manufactured, and alternative alpha-blocker products.

References

1. U.S. Food and Drug Administration. (n.d.). Dibenzyline prescribing information: Phenoxybenzamine hydrochloride capsules. FDA-approved product labeling.

2. National Library of Medicine. (n.d.). Dibenzyline- phenoxybenzamine hydrochloride capsule. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2019). Abbreviated new drug application: ANDA review process. FDA.

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.